Skip to main content

Table 4 Subgroup analysis of disease progression rate

From: Testing whether the progression of Alzheimer’s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data

 Uncorrected disease progression rate, points/year, mean (95% CI)Covariate-corrected disease progression rate, points/year, mean (95% CI)Maximum extent of placebo effect, points mean (95% CI)
Overall5.77 (5.60, 5.94)5.86 (5.75, 5.97)− 1.89 (− 2.08, − 1.69)
Publication year
 < 20086.13 (5.89, 6.39)5.92 (5.80, 6.04)− 1.70 (− 2.04, − 1.36)
 ≥  20085.56 (5.40, 5.73)5.81 (5.72, 5.92)− 2.03 (− 2.24, − 1.81)
Trial design
 Add-on5.53 (5.26, 5.80)5.85 (5.69, 6.00)− 1.92 (− 2.25, − 1.59)
 Non-add-on5.84 (5.64, 6.04)5.87 (5.74, 6.01)− 1.88 (− 2.11, − 1.65)
Regions
 International5.81 (5.66, 5.97)5.78 (5.67, 5.90)− 2.17 (− 2.39, − 1.95)
 North America5.62 (5.35, 5.89)6.11 (6.00, 6.23)− 1.50 (− 1.69, − 1.31)
 Europe/Oceania5.58 (4.68, 6.48)5.54 (4.79, 6.29)− 2.35 (− 3.80, − 0.90)
 East Asia5.67 (5.15, 6.19)5.45 (4.93, 5.97)− 2.43 (− 3.45, − 1.41)
 Middle Asia7.00 (5.98, 8.02)6.76 (6.20, 7.31)− 0.01 (− 1.31, 1.28)
 South America7.27 (6.49, 8.06)6.27 (5.48, 7.06)− 1.35 (− 2.11, − 0.60)
  1. The values have been converted to annual disease progression rate, α (points/week) × 52 weeks/year